Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.
Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer|Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
DRUG: amg 162
Number of Participants Survived, 2 years
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.